Sympathetic overactivity in renal failure controlled by ACE inhibition: Clinical significance

Nephrology Dialysis Transplantation

Volumn 15, Issue 6, 2000, Pages 755-758

  Blankestijn, Peter J ^a   Ligtenberg, Gerry ^a   Klein, Inge H H T ^a   Koomans, Hein A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL;

CHRONIC KIDNEY FAILURE; CLINICAL STUDY; CONTROLLED STUDY; EDITORIAL; HUMAN; HYPERTENSION; PRIORITY JOURNAL; SYMPATHETIC TONE;

EID: 0034023576     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/15.6.755     Document Type: Editorial

References (26)

1. Ligtenberg G, Blankestijn PJ, Oey PL et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999; 340: 1321-1328
2. Ritz E, Koomans HA. New insights into mechanisms of blood pressure regulation in patients with uraemia. Nephrol Dial Transplant 1996; 11 [Suppl 2]: 52-59
3. Campese VM. Neurogenic factors and hypertension in chronic renal failure. J Nephrol 1997; 10: 184-187
4. Levitan D, Massry SG, Romoff M, Campese VM. Plasma catecholamines and autonomic nervous system function in patients with early renal insufficiency and hypertension: effect of clonidine. Hephron 1984; 36: 24-29
5. Laederach K, Weidmann P. Plasma and urinary catecholamines as related to renal function in man. Kidney Int 1987; 31: 107-111
6. Converse RL, Jacobsen TN, Toto R et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327: 1912-1918
7. Klein IHHT, Oey PL, Ligtenberg G, Koomans HA, Blankestijn PJ. Muscle sympathetic nerve activity is increased in patients with early polycystic kidney disease. J Am Soc Nephrol 1999; 10: 79A (abstract)
8. Schalekamp MADH, Schalekamp-Kuyken MPA, de Moor-Fruytier M, Meininger T, Vaandrager-Kranenburg DJ, Birkenhager WH. Interrelationships between blood pressure, renin, renin substrate and blood volume in terminal renal failure. Clin Sci Mol Med 1973; 45: 417-428
9. Weidmann P, Maxweel MH, Lupu AN, Lewin AJ, Massry SG. Plasma renin activity and blood pressure in terminal renal failure. N Engl J Med 1971; 285: 757-762
10. Reid IA. Interactions between ANG II, sympathetic nervous system, and baroreflexes in regulation of blood pressure. Am J Physiol 1992; 262: E763-778
11. Matsukawa T, Gotoh E, Minamisawa K et al. Effects of intravenous infusions of angiotensin II on muscle sympathetic nerve activity in humans. Am J Physiol 1991; 30: R690-696
12. Rump LC. Advantages of Ang-II receptor blockade over ACE inhibition with respect to suppression of sympathetic activity: heartening news for the kidney? Nephrol Dial Transplant 1999; 14: 556-559
13. Katholi RE, Whitlow PL, Hageman GR, Woods WT. Intrarenal adenosine produces hypertension by activating the sympathetic nervous system via the renal nerves in the dog. J Hypertens 1984; 2: 349-359
14. Faber JE, Brody MJ. Afferent renal nerve-dependent hypertension following acute renal artery stenosis in the conscious rat. Circ Res 1985; 57: 676-688
15. Campese VM, Kogosow E, Koss M. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension 1995; 25: 878-882
16. Ye S, Ozgur B, Campese VM. Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. Kidney Int 1997; 51: 722-727
17. Miyajima E, Yamada Y, Yoshida Y et al. Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism. Hypertension 1991; 17: 1057-1062
18. Grassi G, Cattaneo BM, Seravalle G et al. Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Circulation 1997; 96: 1173-1179
19. Grassi G, Turri C, Dell'Oro R, Stella ML, Bolla GB, Mancia G. Effect of chronic angiotensin converting enzyme inhibition on sympathetic nerve traffic and baroreflex control of the circulation in essential hypertension. J Hypertens 1998; 16: 1789-1796
20. Schohn D, Weidmann P, Jahn H, Beretta-Piccoli C. Norepinephrine related mechanisms in hypertension accompanying renal failure. Kidney Int 1985; 28: 814-822
21. Julius S. Sympathetic hyperactivity and coronary risk in hypertension. Hypertension 1993; 21: 886-893
22. Mancia G, Grassi G, Giannattasio C, Seravalle G. Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Circulation 1999; 34: 724-728
23. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A for the V-HeFT VA Cooperative Studies Group. Plasma norepinephrine, plasma renin activity, and congestive heart failure: relations to survival and the effects of therapy in V-HeFT II. Circulation 1993; 87: VI-40 VI-48
24. London GM, Pannier B, Guerin AP, Marchais SJ, Safar ME, Cuche JL. Cardiac hypertrophy, aortic compliance, peripheral resistance and wave reflection in end stage renal disease: comparalive effects of ACE inhibition and calcium channel blockade. Circulation 1994; 90: 2786-2796
25. Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 1981; 304: 930-933
26. Fletcher EC, Bao G, Li R. Renin activity and blood pressure in response to chronic episodic hypoxia. Hypertension 1999; 34: 309-314